Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 6,861 matching trials from the live ClinicalTrials.gov search.

Filters: Orlando, Florida Clear all

Conditions: COVID-19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 3,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 47
States / cities: Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more

Conditions: HIV Infections
Interventions: APRETUDE, Cabotegravir tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 22
States / cities: Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 13 more

Conditions: Solid Tumor
Interventions: BHV-1510, Cemiplimab; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • Palo Alto, California + 14 more

Conditions: Visual Acuity
Interventions: Test Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 5
States / cities: Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 2 more

Conditions: Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
Interventions: Deucravacitinib, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 9 more

Conditions: Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 31
States / cities: Dothan, Alabama • Tucson, Arizona • Newport Beach, California + 27 more

Conditions: Treatment Resistant Depression
Interventions: Liafensine, Placebo; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 41
States / cities: Huntsville, Alabama • Phoenix, Arizona • Garden Grove, California + 36 more

Conditions: Solid Tumor
Interventions: CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 15 more

Conditions: Healthy, Hepatic Insufficiency
Interventions: LY3502970; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Smoking Cessation
Interventions: placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4,595 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 65
States / cities: Mobile, Alabama • Encino, California • Escondido, California + 54 more

Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions: Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy; Combination Product · Drug
Lead sponsor: PDS Biotechnology Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more

Conditions: Cystic Fibrosis
Interventions: Discontinuation of hypertonic saline (HS), Continuation of hypertonic saline (HS); Other
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 128
States / cities: Daphne, Alabama • Mobile, Alabama • Goodyear, Arizona + 94 more

Conditions: Depressive Disorder, Major
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 25
States / cities: Birmingham, Alabama • Glendale, California • Oceanside, California + 22 more

Conditions: Influenza, Human
Interventions: Influenza ModRNA Vaccine, Quadrivalent Influenza Vaccine (QIV); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 32
States / cities: Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 25 more

Conditions: Prostate Cancer
Interventions: Investigators choice of SoC, AAA817; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 35
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide, Dulaglutide, Background therapy Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 30
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 25 more

Conditions: Major Depressive Disorder (MDD)
Interventions: agomelatine, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 51
States / cities: Mesa, Arizona • Los Angeles, California • Oceanside, California + 42 more

Conditions: Overweight, Obese, Type 1 Diabetes Mellitus
Interventions: CT-868, CT-868 Pen Injector, CT-868 Pen Injector, Placebo; Drug · Device
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Concord, California • Escondido, California • Aurora, Colorado + 17 more

Conditions: Breast Cancer
Interventions: Palbociclib, Standard Adjuvant Endocrine Therapy; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 5,796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 192
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more

Conditions: Locally Advanced/Metastatic Solid Tumors
Interventions: HY-0102; Drug
Lead sponsor: Shanghai HyaMab Biotech Co.,Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Orlando, Florida • Las Vegas, Nevada • Tyler, Texas

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 12 Years to 18 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Obesity
Interventions: Glucagon, Placebo; Drug
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Hypertension
Interventions: Rheos® Baroreflex Hypertension System; Device
Lead sponsor: CVRx, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more

Search by objective public record fields.

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Evaluation of Rotation With a Multifocal Toric Contact Lens

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Real-life Effectiveness of Vortioxetine in Depression

A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

A Study of CT-868 in Type 1 Diabetes Mellitus

PALbociclib CoLlaborative Adjuvant Study

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes

Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects

Rheos® Pivotal Trial